China is one of the leading nations in the development of cell and gene therapies and is the second largest in the world for CAR-T clinical trials.
With government hands-on support, increased specialised workforce, rapid build-out of 200 or more robust therapies pipeline under production capacity, and driving the next wave of innovation, precision manufacturing and tailored therapies that are unlocking China’s full potential to be the leading manufacturer of next-generation cell and gene therapies.
Part of the 6th Biopharma Development Week, Informa Connect’s 2nd Cell and Gene Therapy Manufacturing summit will be one of 3 colocated events spanning the biopharma market value chain. Spotlights on current regulations, commercialisation, clinical trials market, pricing and alongside benchmarking global standards.
- 2 Day Conference: CNY 7,000
- BDP Party: CNY 350
- Start Up Rate: CNY 2,450